Approaching sites of action of drugs in clinical pharmacology: New analytical options and their challenges. Issue 3 (15th September 2020)

• Record Type: Journal Article
• Authors: Longuespée, Rémi; Theile, Dirk; Fresnais, Margaux; Burhenne, Jürgen; Weiss, Johanna; Haefeli, Walter E.
• Is Part Of: British journal of clinical pharmacology. Volume 87:Issue 3(2021)
• Page Start: 858
• Page End: 874
• Publication Date: 2020-09-15
• Subjects: clinical pharmacology -- mass spectrometry -- personalized medicine -- review -- sites of action; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.14543
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Clinical pharmacology is an important discipline for drug development aiming to define pharmacokinetics (PK), pharmacodynamics (PD) and optimum exposure to drugs, i.e. the concentration–response relationship and its modulators. For this purpose, information on drug concentrations at the anatomical, cellular and molecular sites of action is particularly valuable. In pharmacological assays, the limited accessibility of target cells in readily available samples (i.e. blood) often hampers mass spectrometry‐based monitoring of the absolute quantity of a compound and the determination of its molecular action at the cellular level. Recently, new sample collection methods have been developed for the specific capture of rare circulating cells, especially for the diagnosis of circulating tumour cells. In parallel, new advances and developments in mass spectrometric instrumentation now allow analyses to be scaled down to the cellular level. Together, these developments may permit the monitoring of minute drug quantities and show their effect at the cellular level. In turn, such PK/PD associations on a cellular level would not only enrich our pharmacological knowledge of a given compound but also expand the basis for PK/PD simulations. In this review, we describe novel concepts supporting clinical pharmacology at the anatomical, cellular and molecular sites of action, and highlight the new challenges in mass spectrometry‐based monitoring. Moreover, we present methods to tackle these challenges and define future needs.